Montine TJ - Search Results

1

Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes.

Jun G, Naj AC, Beecham GW, Wang LS, Buros J, Gallins PJ, Buxbaum JD, Ertekin-Taner N, Fallin MD, Friedland R, Inzelberg R, Kramer P, Rogaeva E, St George-Hyslop P; Alzheimer's Disease Genetics Consortium; Cantwell LB, Dombroski BA, Saykin AJ, Reiman EM, Bennett DA, Morris JC, Lunetta KL, Martin ER, Montine TJ, Goate AM, Blacker D, Tsuang DW, Beekly D, Cupples LA, Hakonarson H, Kukull W, Foroud TM, Haines J, Mayeux R, Farrer LA, Pericak-Vance MA, Schellenberg GD. Jun G, et al. Among authors: montine tj. Arch Neurol. 2010 Dec;67(12):1473-84. doi: 10.1001/archneurol.2010.201. Epub 2010 Aug 9. Arch Neurol. 2010. PMID: 20697030 Free PMC article.

2

4-hydroxy-2-nonenal pyrrole adducts in human neurodegenerative disease.

Montine KS, Kim PJ, Olson SJ, Markesbery WR, Montine TJ. Montine KS, et al. Among authors: montine tj. J Neuropathol Exp Neurol. 1997 Aug;56(8):866-71. doi: 10.1097/00005072-199708000-00004. J Neuropathol Exp Neurol. 1997. PMID: 9258256

3

Distribution of reducible 4-hydroxynonenal adduct immunoreactivity in Alzheimer disease is associated with APOE genotype.

Montine KS, Reich E, Neely MD, Sidell KR, Olson SJ, Markesbery WR, Montine TJ. Montine KS, et al. Among authors: montine tj. J Neuropathol Exp Neurol. 1998 May;57(5):415-25. doi: 10.1097/00005072-199805000-00005. J Neuropathol Exp Neurol. 1998. PMID: 9596412

4

Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease.

Montine TJ, Markesbery WR, Morrow JD, Roberts LJ 2nd. Montine TJ, et al. Ann Neurol. 1998 Sep;44(3):410-3. doi: 10.1002/ana.410440322. Ann Neurol. 1998. PMID: 9749613

5

Apolipoprotein E allelic influence on human cerebrospinal fluid apolipoproteins.

Montine KS, Bassett CN, Ou JJ, Markesbery WR, Swift LL, Montine TJ. Montine KS, et al. Among authors: montine tj. J Lipid Res. 1998 Dec;39(12):2443-51. J Lipid Res. 1998. PMID: 9831633 Free article.

6

No difference in plasma or urinary F2-isoprostanes among patients with Huntington's disease or Alzheimer's disease and controls.

Montine TJ, Shinobu L, Montine KS, Roberts LJ 2nd, Kowall NW, Beal MF, Morrow JD. Montine TJ, et al. Among authors: montine ks. Ann Neurol. 2000 Dec;48(6):950. Ann Neurol. 2000. PMID: 11117557 No abstract available.

7

Cerebrospinal fluid abeta42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls.

Montine TJ, Kaye JA, Montine KS, McFarland L, Morrow JD, Quinn JF. Montine TJ, et al. Among authors: montine ks. Arch Pathol Lab Med. 2001 Apr;125(4):510-2. doi: 10.5858/2001-125-0510-CFATAF. Arch Pathol Lab Med. 2001. PMID: 11260625 Free article.

8

Expression and activities of aldo-keto oxidoreductases in Alzheimer disease.

Picklo MJ, Olson SJ, Markesbery WR, Montine TJ. Picklo MJ, et al. Among authors: montine tj. J Neuropathol Exp Neurol. 2001 Jul;60(7):686-95. doi: 10.1093/jnen/60.7.686. J Neuropathol Exp Neurol. 2001. PMID: 11444797

9

Lipid peroxidation in aging brain and Alzheimer's disease.

Montine TJ, Neely MD, Quinn JF, Beal MF, Markesbery WR, Roberts LJ, Morrow JD. Montine TJ, et al. Free Radic Biol Med. 2002 Sep 1;33(5):620-6. doi: 10.1016/s0891-5849(02)00807-9. Free Radic Biol Med. 2002. PMID: 12208348 Review.

10

Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease.

Montine TJ, Quinn JF, Milatovic D, Silbert LC, Dang T, Sanchez S, Terry E, Roberts LJ 2nd, Kaye JA, Morrow JD. Montine TJ, et al. Ann Neurol. 2002 Aug;52(2):175-9. doi: 10.1002/ana.10272. Ann Neurol. 2002. PMID: 12210787

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

540 results

Search Page